tiprankstipranks
Trending News
More News >

Starpharma Announces Cessation of Performance Rights

Story Highlights
Starpharma Announces Cessation of Performance Rights

Don’t Miss TipRanks’ Half-Year Sale

Starpharma Holdings Limited ( (AU:SPL) ) just unveiled an update.

Starpharma Holdings Limited announced the cessation of 716,375 performance rights due to unmet conditions, impacting its issued capital structure. This development may affect stakeholders’ perceptions of the company’s operational progress and could influence its market positioning by highlighting challenges in meeting performance targets.

More about Starpharma Holdings Limited

Starpharma Holdings Limited operates within the pharmaceutical industry, focusing on the development of innovative medical solutions, particularly in the area of dendrimer-based products. The company is known for its work in drug delivery and development of novel therapeutics with a market focus on enhancing the performance of pharmaceuticals.

YTD Price Performance: -17.27%

Average Trading Volume: 384,930

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$38.06M

See more data about SPL stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1